Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation.

IF 1.5 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-17 DOI:10.1080/14737167.2025.2518135

Lili Su, Xiangyu Zhang, Mengrong Li, Ying Li, Dong Wang

{"title":"Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation.","authors":"Lili Su, Xiangyu Zhang, Mengrong Li, Ying Li, Dong Wang","doi":"10.1080/14737167.2025.2518135","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the cost-effectiveness of osimertinib compared to dacomitinib for advanced non-small cell lung cancer with EGFR mutation from the perspective of China's health system.Methods: Based on the FLAURA clinical trial and network meta-analysis, a partitioned survival model was constructed with a model simulation timeframe of 10 years and a 3-week cycle. Cost and quality-adjusted life years (QALYs) were used as model output indicators, and the incremental cost-effectiveness ratio was calculated to determine the economic feasibility of osimertinib compared to dacomitinib through cost-utility analysis. Sensitivity analysis was applied to test the robustness of the model.Results: The basic analysis results indicate that the osimertinib group incurred an additional cost of 138,487 Chinese Yuan (CNY) compared to the dacomitinib group, but gained an additional 0.32 QALYs. The incremental cost-effectiveness ratio is 436,203 CNY, which is higher than three times China's per capita GDP.Conclusion: Under the threshold of three times China's per capita GDP, osimertinib appears not to be cost-effective compared to dacomitinib.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-8"},"PeriodicalIF":1.5000,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2025.2518135","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the cost-effectiveness of osimertinib compared to dacomitinib for advanced non-small cell lung cancer with EGFR mutation from the perspective of China's health system.

Methods: Based on the FLAURA clinical trial and network meta-analysis, a partitioned survival model was constructed with a model simulation timeframe of 10 years and a 3-week cycle. Cost and quality-adjusted life years (QALYs) were used as model output indicators, and the incremental cost-effectiveness ratio was calculated to determine the economic feasibility of osimertinib compared to dacomitinib through cost-utility analysis. Sensitivity analysis was applied to test the robustness of the model.

Results: The basic analysis results indicate that the osimertinib group incurred an additional cost of 138,487 Chinese Yuan (CNY) compared to the dacomitinib group, but gained an additional 0.32 QALYs. The incremental cost-effectiveness ratio is 436,203 CNY, which is higher than three times China's per capita GDP.

Conclusion: Under the threshold of three times China's per capita GDP, osimertinib appears not to be cost-effective compared to dacomitinib.

查看原文本刊更多论文

奥西替尼和达科替尼一线治疗晚期非小细胞肺癌EGFR突变的成本-效用分析。

目的：从中国卫生系统的角度评价奥西替尼与达克米替尼治疗晚期非小细胞肺癌EGFR突变的成本-效果。方法：基于FLAURA临床试验和网络meta分析，构建分区生存模型，模型模拟时间框架为10年，周期为3周。以成本和质量调整生命年（QALYs）作为模型输出指标，计算增量成本-效果比，通过成本-效用分析确定奥希替尼与达科替尼比较的经济可行性。采用敏感性分析检验模型的稳健性。结果：基础分析结果显示，与达克替尼组相比，奥西替尼组的额外成本为138,487元人民币（CNY），但获得了0.32个qaly。增量成本效益比为436203元，高于中国人均GDP的3倍以上。结论：在中国人均GDP的3倍阈值下，奥西替尼与达克替尼相比似乎不具有成本效益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Pharmacoeconomics & Outcomes Research HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY

CiteScore

4.00

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.